The AGMT MALT-2 trial is the first phase II study exploring the efficacy and safety of R-lenalidomide in MALT lymphoma patients. With a response rate of 80% this study shows that the combination is feasible and active irrespective of inital site or prior treatment.
Home / Resource Library / A phase II study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)